Author/Authors :
Taheraghdam, Ali Akbar tabriz university of medical sciences - Neurosciences Research Center (NSRC), ايران , Sharifipour, Ehsan tabriz university of medical sciences - Neurosciences Research Center (NSRC), Imam Reza Hospital - Department of Neurology, Student Research Committee, ايران , Pashapour, Ali tabriz university of medical sciences - Neurosciences Research Center (NSRC), ايران , Namdar, Shahryar tabriz university of medical sciences, ايران , Hatami, Abolfazl tabriz university of medical sciences - Neurosciences Research Center (NSRC), ايران , Houshmandzad, Samaneh tabriz university of medical sciences - Neurosciences Research Center (NSRC), ايران , Sadeghihokmabadi, Elyar tabriz university of medical sciences, ايران , Tazik, Mokhtar tabriz university of medical sciences, ايران , Rikhtegar, Reza tabriz university of medical sciences - Neurosciences Research Center (NSRC), Imam Reza Hospital - Department of Neurology, Student Research Committee, ايران , Mahmoodpoor, Ata tabriz university of medical sciences, ايران
Abstract :
Objectives: To assess the clinical relevance (functional outcome) of a 3-month allopurinol regimen in patients with high serum uric acid (SUA) levels and acute ischemic stroke without considering the changes in SUA levels. Materials and Methods: In a randomized, double-blind, controlled study, 70 patients (45 females, 25 males) with acute ischemic stroke who had elevated levels of SUA were included. They were divided in two 35-patient groups to investigate the effect of 3 months of an allopurinol (200 mg/day) regimen versus placebo on their functional outcome, which was evaluated using a modified Rankin scale. Results: The overall mean age was 68.9 ± 11.33 years (range 27–89). The final favorable functional status (mRS = 0–2) was 23 (65.7%) and 14 (40.0%) in the treated and placebo groups, respectively, which was strongly associated with allopurinol consumption (OR = 4.646, p = 0.014) and age ≤ 70 years (OR = 0.139, p = 0.005) in patients with ischemic stroke after adjusting for confounders. There was no significant difference in death between allopurinol-treated cases (3; 8.6%) and placebotreated ones (6; 17.2%; p = 0.278). Conclusion: Allopurinol treatment was well tolerated and improved the 3-month functional status of patients with acute ischemic stroke who had high levels of SUA without considering the decreasing effect of allopurinol on SUA.
